Tokyo, Japan, December 1, 2014 ― Sandoz, the generic pharmaceutical division of Novartis, today announced the launch in Japan of biosimilar Filgrastim BS Injection 75µg / 150µg / 300µg Syringe. Filgrastim is used with certain cancer patients to accelerate recovery of infection-fighting white blood cells after chemotherapy (prevention of neutropenia) and is also used to stimulate mobilization of hematopoietic stem cells for collection and transplantation.

“As the pioneer and global leader in biosimilars we are very pleased to announce the launch of our second …